Oncogene Inhibitors Market Sales Revenue Clinical Trials Pipeline Report 2015

Oncogenomics is an emerging field that involves screening of genes that may be involved in cancer development. Human genome consists of 23 chromosomal pairs, approximately 20,000- 25,000 genes and 3,234.83 Mb genome size. Oncogene addiction is a phenomenon in which cancer could be checked by deactivating single oncogene. Proto-onco genes are main target of investigators because they may convert into oncogenes at any stage of life. Sequence level similarity and identification of genetic factors are expected to shed more light on their working. It will allow the investigators to develop drugs capable of preventing oncogene activation and activity in the body. Development of such therapeutics is a daunting task because human genome is quite big and consists of variety of genes whose function has yet to be determined by investigators.

Download Report:

https://www.kuickresearch.com/report-Oncogene-Inhibitors-Market-&-Pipeline-Insight-2015.php

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

"Oncogene Inhibitors Market & Pipeline Insight 2015" Table of Contents

1. Introduction to Oncogene Inhibitors

2. Mechanism of Oncogene Inhibitors

3. Global Oncogene Inhibitors Market Overview
3.1 Current Market Scenario
3.2 Oncogene Inhibitors Clinical Pipeline Insight

4. Global Oncogene Inhibitor Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges

5. Global Oncogene Inhibitor Market Future Prospects

6. Oncogene Protein Inhibitors Pipeline by Company, Indication & Phase
6.1 Preclinical
6.2 Suspended & Discontinued

7. Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Company, Indication & Phase
7.1 Research till Preregistration
7.2 Marketed Drug Clinical Insight
7.3 Suspended & Discontinued

8. Proto Oncogene Protein b raf Inhibitors Pipeline by Company, Indication & Phase
8.1 Research till Phase-III
8.2 Marketed Drug Clinical Insight
8.3 Suspended & Discontinued

9. Proto Oncogene Protein c-kit Inhibitors Pipeline by Company, Indication & Phase
9.1 Research till Preregistration
9.2 Marketed Drug Clinical Insight
9.3 Suspended & Discontinued

10. Proto-Oncogene Protein c-rel Inhibitors Pipeline by Company, Indication & Phase
10.1 Research

11. Proto Oncogene Protein c-akt Inhibitors Pipeline by Company, Indication & Phase
11.1 Preclinical till Phase-III
11.2 Suspended & Discontinued

12. Proto Oncogene Protein c met Inhibitors Pipeline by Company, Indication & Phase
12.1 Preclinical till Phase-III
12.2 Marketed Drug Clinical Insight
12.3 Suspended & Discontinued

13. Proto Oncogene Protein c ret Inhibitors Pipeline by Company, Indication & Phase
13.1 Preclinical till Phase-III
13.2 Marketed Drug Clinical Insight
13.3 Suspended & Discontinued

14. Proto-Oncogene Protein c mdm2 Inhibitors Pipeline by Company, Indication & Phase
14.1 Preclinical till Phase-I/II
14.2 Suspended & Discontinued

15. Proto-Oncogene Protein Inhibitors Pipeline by Company, Indication & Phase
15.1 Preclinical

16. Proto-Oncogene-Protein-c-ets Inhibitors Pipeline by Company, Indication & Phase
16.1 Preclinical

17. Proto-Oncogene Protein c-fli-1 Inhibitors Pipeline by Company, Indication & Phase
17.1 Preclinical

18. Proto Oncogene Proteins c pim 1 Inhibitors Pipeline by Company, Indication & Phase
18.1 Preclinical till Phase-I/II
18.2 Suspended & Discontinued

19. Proto Oncogene Protein c-myc Inhibitors Pipeline by Company, Indication & Phase
19.1 Preclinical till Phase-I/II
19.2 Marketed Drug Clinical Insight

20. Proto Oncogene Proteins c raf Inhibitors Pipeline by Company, Indication & Phase
20.1 Suspended & Discontinued

21. Proto Oncogene Proteins c myb Inhibitors Pipeline by Company, Indication & Phase

22. Multiple Oncogene Inhibitors Pipeline by Company, Indication & Phase
22.1 Preclinical till Registered
22.2 Marketed Drug Clinical Insight
22.3 Suspended & Discontinued

23. Competitive Landscape
23.1 AstraZeneca
23.2 ArQule Inc
23.3 Biogen Idec
23.4 Boehringer Ingelheim
23.5 Celgene Corporation
23.6 Constellation Pharmaceutical
23.7 Epizyme Pharmaceutical
23.8 Genentech
23.9 GalaxoSmithKline
23.10 Incyte Corporation
23.11 Johnson & Johnson
23.12 Merck
23.13 Novartis
23.14 Onyx pharmaceuticals
23.15 Pfizer

Figure 1-1: Features of Oncogenes
Figure 1-2: Types of Genes
Figure 1-3:Factors Responsible for Conversion of Proto-Oncogenes to Oncogenes
Figure 2-1: Activation of Proto-Oncogenes to Oncogenes
Figure 2-2:Benefits of Oncogene Inhibitors
Figure 2-3: Mechanism of Crizotinib
Figure 2-4: Mechanism of Vemurafenib
Figure 2-5: Mechanism of Vorinostat
Figure 3-1: Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(%), 2015
Figure 3-2: Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(Number), 2015
Figure 3-3: Discontinued Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(%), 2015
Figure 3-4: Discontinued Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(Number), 2015
Figure 3-5: Proto Oncogene Protein b raf Inhibitors Pipeline by Phase(%), 2015
Figure 3-6: Proto Oncogene Protein b raf Inhibitors Pipeline by Phase(Number), 2015
Figure 3-7: Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(%), 2015
Figure 3-8: Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(Number), 2015
Figure 3-9: Discontinued Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(%), 2015
Figure 3-10: Discontinued Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(Number), 2015
Figure 3-11: Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(%), 2015
Figure 3-12: Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(Number), 2015
Figure 3-13: Discontinued Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(%), 2015
Figure 3-14: Discontinued Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(Number), 2015
Figure 3-15: Proto Oncogene Protein c met Inhibitors Pipeline by Phase(%), 2015
Figure 3-16: Proto Oncogene Protein c met Inhibitors Pipeline by Phase(Number), 2015
Figure 3-17: Discontinued Proto Oncogene Protein c met Inhibitors Pipeline by Phase(%), 2015
Figure 3-18: Discontinued Proto Oncogene Protein c met Inhibitors Pipeline by Phase(Number), 2015
Figure 3-19: Proto Oncogene Protein c ret Inhibitors Pipeline by Phase(%), 2015
Figure 3-20: Proto Oncogene Protein c ret Inhibitors Pipeline by Phase(Number), 2015
Figure 3-21: Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(%), 2015
Figure 3-22: Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(Number), 2015
Figure 3-23: Discontinued Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(%), 2015
Figure 3-24: Discontinued Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(Number), 2015
Figure 3-25: Proto Oncogene Protein c pim 1 Inhibitors Pipeline by Phase(%), 2015
Figure 3-26: Proto Oncogene Protein c pim 1 Inhibitors Pipeline by Phase(Number), 2015
Figure 3-27: Proto Oncogene Protein c-myc Inhibitors Pipeline by Phase(%), 2015
Figure 3-28: Proto Oncogene Protein c-myc Inhibitors Pipeline by Phase(Number), 2015
Figure 3-29: Multiple Oncogene Inhibitors Pipeline by Phase(%), 2015
Figure 3-30: Multiple Oncogene Inhibitors Pipeline by Phase(number), 2015
Figure 3-31: Discontinued Multiple Oncogene Inhibitors Pipeline by Phase(%), 2015
Figure 3-32: : Discontinued Multiple Oncogene Inhibitors Pipeline by Phase(Number), 2015
Figure 4-1: Oncogene Inhibitor Market Favorable Parameters
Figure 4-2: Commercialization Challenges to Oncogene Inhibitors

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.